A case of culture-positive peritonitis resistant to treatment

Clinical Nephrology

Volumn 71, Issue 1, 2009, Pages 100-102

  Unver, Suatunver ^a   Atasoyu, E M ^a   Uluutku, H ^a   Sucullu, I ^a   Yildirim, S ^a   Evrenkaya, T R ^a  

^a GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; CEFAZOLIN; MEROPENEM; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; BACTERIUM CULTURE; BLOOD CULTURE; CASE REPORT; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DIALYSATE; ECHOGRAPHY; FEMALE; FEVER; HEMODIALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LABORATORY TEST; LAPAROTOMY; LETTER; LOW DRUG DOSE; MALE; NAUSEA AND VOMITING; NONHUMAN; PERITONEAL DIALYSIS; PERITONITIS; PSEUDOMONAS AERUGINOSA; SURGICAL DRAINAGE; TREATMENT DURATION; KIDNEY FAILURE; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PATHOLOGY; PSEUDOMONAS INFECTION;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; PERITONITIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 63249088841     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71100     Document Type: Letter

References (11)

1. Dutranoy JC, Molle G. Sclerosing peritonitis. J Chir. 2005; 142: 78-84.
2. Evrenkaya TR, Atasoyu EM, Unver S, Basekim C, Baloglu H, Tulbek MY. Corticosteroid and tamoxifen therapy in sclerosing encapsulating peritonitis in a patient on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2004; 19: 2423-2424.
3. Hockensmith ML, Madinger NE, Teitelbaum I. Concerns regarding recommendations for the treatment of CAPD peritonitis. Perit Dial Int. 2001; 21: 317-319, author reply 320-321.
4. Honda K, Oda H. Pathology of encapsulating peritoneal sclerosis. Perit Dial Int. 2005; 25 (Suppl 4): S19-S29.
5. Ishii Y, Sawada T, Shimizu A et al. An experimental sclerosing encapsulating peritonitis model in mice. Nephrol Dial Transplant 2001; 16: 1262-1266.
6. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int. 2001; 21: 417-418.
7. Kawaguchi Y, Kawanishi H, Fukui H, Hara S, Imada A, Kubo H, Kin M, Nokomoto M, Ohira S, Shoji T. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis. 2004; 44: 729-737.
8. Keane WF, Bailie GR, Boeschoten E, Gokal R, Golper TA, Holmes CJ, Kawaguchi Y, Piraino B, Riella M, Vas S. International Society for Peritoneal Dialysis. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Perit Dial Int. 2000; 20: 396-411.
9. Ozener C, Kiris S, Lawrence R et al. Potential beneficial effect of tamoxifen in retroperitoneal fibrosis. Nephrol Dial Transplant. 1997; 12: 2166-2168.
10. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A, Holmes C, Kuijper EJ, Li PK, Lye WC, Mujais S, Paterson DL, Fontan MP, Ramos A, Schaefer F, Uttley L. ISPD Ad Hoc Advisory Committee. Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int. 2005; 25: 107-131.
11. Rigby RJ, Hawley CM. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13: 154-159.